Hormonal
Acarbose and metformin provide similar HbA1c reduction and modest weight loss in newly diagnosed Chinese type 2 diabetic patients regardless of BMI status.
For newly diagnosed Chinese type 2 diabetics, both acarbose (300mg/day) and metformin (1500mg/day) are effective first-line treatments for lowering HbA1c and achieving modest weight loss, regardless of whether you are normal weight, overweight, or obese. Acarbose may offer slightly better weight loss in overweight individuals, while metformin may be better for fasting blood glucose. The choice depends on individual tolerance and dietary habits, particularly carbohydrate intake.
Acarbose and metformin decreased HbA1c levels similarly regardless of BMI status of Chinese type 2 diabetic patients. Acarbose and metformin resulted in a significant and modest improvement of anthropometric parametres in different BMI status.
Why this rating
Randomized, open-label, non-inferiority trial with 784 subjects.
Source
MARCH2: Comparative Assessment of Therapeutic Effects of Acarbose and Metformin in Newly Diagnosed Type 2 Diabetes Patients
Guang Wang et al. · PLoS ONE · 2014
DOI 10.1371/journal.pone.0105698
More from this paper
- In overweight patients, metformin is superior to acarbose for lowering fasting blood glucose, while acarbose is superior to metformin for lowering 2-hour post-challenge blood glucose.Good
- Metformin is superior to acarbose for improving insulin resistance in normal weight patients, while both drugs are similar in overweight and obese patients.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →